<p>根据 MarketBeat.com 的报道，目前覆盖 Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）的十三位分析师一致推荐该股票为 “持有”。其中一位分析师给予该股票 “卖出” 评级，十位分析师给予 “持有” 评级，一位分析师给予 “买入” 评级，另一位分析师给予 “强烈买入” 评级。在过去一年中，发布报告的经纪商对该股票的平均十二个月目标价为 48.4444 美元。</p>
<p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
<p>多位分析师对该公司发布了报告。HC Wainwright 将 Rapt Therapeutics 的评级从 “买入” 下调至 “中性”，并设定了 58.00 美元的目标价。Clear Str 在 1 月 20 日的报告中将 Rapt Therapeutics 的股票评级从 “强烈买入” 下调至 “持有”。巴克莱在 1 月 21 日的研究报告中将 Rapt Therapeutics 的股票评级从 “超配” 下调至 “等权重”，并设定了 58.00 美元的目标价。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 Rapt Therapeutics 的 “卖出（d-）” 评级。最后，TD Cowen 在 1 月 20 日的报告中将 Rapt Therapeutics 的股票评级从 “买入” 下调至 “持有”。</p>
<p><strong>获取我们最新的 Rapt Therapeutics 股票分析</strong></p>
<h2>机构投资者对 Rapt Therapeutics 的看法</h2>
<p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的持股增加了 173.4%。Susquehanna International Group LLP 目前拥有该公司价值 117 万美元的 45,382 股股票，在此期间又购买了 28,782 股。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 75.2%。Millennium Management LLC 目前拥有该公司价值 101.3 万美元的 39,278 股股票，在此期间又购买了 16,854 股。Ameriprise Financial Inc.在第三季度获得了 Rapt Therapeutics 的新股份，价值约 132.6 万美元。Bridgeway Capital Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 32.0%。Bridgeway Capital Management LLC 目前拥有该公司价值 53.2 万美元的 20,625 股股票，在此期间又购买了 5,000 股。最后，瑞银集团在第三季度将其在 Rapt Therapeutics 的持股增加了 680.3%。瑞银集团目前拥有该公司价值 74.3 万美元的 28,808 股股票，在上个季度又购买了 25,116 股。对冲基金和其他机构投资者持有该公司 99.09% 的股票。</p>
<h2>Rapt Therapeutics 股价上涨 0.0%</h2>
<p>RAPT 股票在周五开盘价为 57.69 美元。该公司的 50 日移动平均价为 40.61 美元，200 日移动平均价为 27.98 美元。Rapt Therapeutics 的 12 个月最低价为 5.67 美元，最高价为 57.86 美元。该公司的市值为 16 亿美元，市盈率为-5.22，贝塔值为 0.47。</p>
<p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.65 美元，超出分析师一致预期的-0.88 美元，超出幅度为 0.23 美元。整体来看，股票分析师预测 Rapt Therapeutics 在当前年度的每股收益为-2.14 美元。</p>
<h2>Rapt Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家临床阶段的生物技术公司，致力于开发用于自身免疫和过敏性疾病的新型治疗药物。公司成立于 2013 年，总部位于加利福尼亚州圣地亚哥，RAPT 运用组织选择性免疫学设计小分子和生物制剂候选药物，以调节免疫细胞的迁移和组织驻留途径。公司的研究平台能够识别驱动组织炎症的靶点，旨在实现比现有疗法更好的疗效和安全性。</p>
<p>公司的主要资产 RPT193 是一种口服可用的 CC 趋化因子受体 4（CCR4）拮抗剂，目前正在进行特应性皮炎和过敏性哮喘的临床开发。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Rapt Therapeutics 吗？</h2>
<p>在考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Rapt Therapeutics 并不在名单上。</p>
<p>虽然 Rapt Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

美国制药 ETF - iShares

<p>Rapt Therapeutics（纳斯达克代码：RAPT）获得了十三位分析师的 “持有” 共识推荐。评级包括一项卖出、十项持有、一项买入和一项强买入。平均目标价格为 48.44 美元。最近的评级下调包括 HC Wainwright 和 TD Cowen，而机构投资者则显著增加了他们的持股。RAPT 的股票开盘价为 57.69 美元，市值为 16 亿美元，市盈率为-5.22。该公司专注于开发针对自身免疫和过敏疾病的治疗药物，其主要资产 RPT193 正在进行临床开发</p>

<p>Shares of Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) have been given a consensus recommendation of &#34;Hold&#34; by the thirteen analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, ten have issued a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $48.4444.</p>
<div class="lb-trans"><p>根据 MarketBeat.com 的报道，目前覆盖 Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）的十三位分析师一致推荐该股票为 “持有”。其中一位分析师给予该股票 “卖出” 评级，十位分析师给予 “持有” 评级，一位分析师给予 “买入” 评级，另一位分析师给予 “强烈买入” 评级。在过去一年中，发布报告的经纪商对该股票的平均十二个月目标价为 48.4444 美元。</p>
</div><p>Get <strong>Rapt Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rapt Therapeutics</strong> 的提醒：</p>
</div><p>A number of analysts have issued reports on the company. HC Wainwright downgraded Rapt Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and set a $58.00 target price for the company. in a research note on Tuesday, January 20th. Clear Str lowered shares of Rapt Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 20th. Barclays downgraded shares of Rapt Therapeutics from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $58.00 target price on the stock. in a research note on Wednesday, January 21st. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Rapt Therapeutics in a research note on Thursday, January 22nd. Finally, TD Cowen downgraded shares of Rapt Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, January 20th.</p>
<div class="lb-trans"><p>多位分析师对该公司发布了报告。HC Wainwright 将 Rapt Therapeutics 的评级从 “买入” 下调至 “中性”，并设定了 58.00 美元的目标价。Clear Str 在 1 月 20 日的报告中将 Rapt Therapeutics 的股票评级从 “强烈买入” 下调至 “持有”。巴克莱在 1 月 21 日的研究报告中将 Rapt Therapeutics 的股票评级从 “超配” 下调至 “等权重”，并设定了 58.00 美元的目标价。Weiss Ratings 在 1 月 22 日的研究报告中重新发布了对 Rapt Therapeutics 的 “卖出（d-）” 评级。最后，TD Cowen 在 1 月 20 日的报告中将 Rapt Therapeutics 的股票评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>Get Our Latest Stock Analysis on Rapt Therapeutics</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Rapt Therapeutics 股票分析</strong></p>
</div><h2>Institutional Investors Weigh In On Rapt Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Rapt Therapeutics 的看法</h2>
</div><p>Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Susquehanna International Group LLP raised its holdings in Rapt Therapeutics by 173.4% in the 3rd quarter. Susquehanna International Group LLP now owns 45,382 shares of the company's stock valued at $1,170,000 after buying an additional 28,782 shares during the period. Millennium Management LLC boosted its stake in Rapt Therapeutics by 75.2% during the third quarter. Millennium Management LLC now owns 39,278 shares of the company's stock worth $1,013,000 after buying an additional 16,854 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Rapt Therapeutics during the third quarter valued at about $1,326,000. Bridgeway Capital Management LLC raised its stake in shares of Rapt Therapeutics by 32.0% in the 3rd quarter. Bridgeway Capital Management LLC now owns 20,625 shares of the company's stock valued at $532,000 after acquiring an additional 5,000 shares during the period. Finally, UBS Group AG lifted its holdings in shares of Rapt Therapeutics by 680.3% in the 3rd quarter. UBS Group AG now owns 28,808 shares of the company's stock worth $743,000 after acquiring an additional 25,116 shares during the last quarter. Hedge funds and other institutional investors own 99.09% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近增加或减少了对该公司的持股。Susquehanna International Group LLP 在第三季度将其在 Rapt Therapeutics 的持股增加了 173.4%。Susquehanna International Group LLP 目前拥有该公司价值 117 万美元的 45,382 股股票，在此期间又购买了 28,782 股。Millennium Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 75.2%。Millennium Management LLC 目前拥有该公司价值 101.3 万美元的 39,278 股股票，在此期间又购买了 16,854 股。Ameriprise Financial Inc.在第三季度获得了 Rapt Therapeutics 的新股份，价值约 132.6 万美元。Bridgeway Capital Management LLC 在第三季度将其在 Rapt Therapeutics 的持股增加了 32.0%。Bridgeway Capital Management LLC 目前拥有该公司价值 53.2 万美元的 20,625 股股票，在此期间又购买了 5,000 股。最后，瑞银集团在第三季度将其在 Rapt Therapeutics 的持股增加了 680.3%。瑞银集团目前拥有该公司价值 74.3 万美元的 28,808 股股票，在上个季度又购买了 25,116 股。对冲基金和其他机构投资者持有该公司 99.09% 的股票。</p>
</div><h2>Rapt Therapeutics Trading Up 0.0%</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 股价上涨 0.0%</h2>
</div><p>RAPT stock opened at $57.69 on Friday. The firm has a 50-day moving average of $40.61 and a two-hundred day moving average of $27.98. Rapt Therapeutics has a 12 month low of $5.67 and a 12 month high of $57.86. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -5.22 and a beta of 0.47.</p>
<div class="lb-trans"><p>RAPT 股票在周五开盘价为 57.69 美元。该公司的 50 日移动平均价为 40.61 美元，200 日移动平均价为 27.98 美元。Rapt Therapeutics 的 12 个月最低价为 5.67 美元，最高价为 57.86 美元。该公司的市值为 16 亿美元，市盈率为-5.22，贝塔值为 0.47。</p>
</div><p>Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.88) by $0.23. As a group, equities analysts forecast that Rapt Therapeutics will post -2.14 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rapt Therapeutics（NASDAQ:RAPT - 获取免费报告）最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为-0.65 美元，超出分析师一致预期的-0.88 美元，超出幅度为 0.23 美元。整体来看，股票分析师预测 Rapt Therapeutics 在当前年度的每股收益为-2.14 美元。</p>
</div><h2>Rapt Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Rapt Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>RAPT Therapeutics, Inc NASDAQ: RAPT is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company's research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.</p>
<div class="lb-trans"><p>RAPT Therapeutics, Inc NASDAQ: RAPT 是一家临床阶段的生物技术公司，致力于开发用于自身免疫和过敏性疾病的新型治疗药物。公司成立于 2013 年，总部位于加利福尼亚州圣地亚哥，RAPT 运用组织选择性免疫学设计小分子和生物制剂候选药物，以调节免疫细胞的迁移和组织驻留途径。公司的研究平台能够识别驱动组织炎症的靶点，旨在实现比现有疗法更好的疗效和安全性。</p>
</div><p>The company's lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.</p>
<div class="lb-trans"><p>公司的主要资产 RPT193 是一种口服可用的 CC 趋化因子受体 4（CCR4）拮抗剂，目前正在进行特应性皮炎和过敏性哮喘的临床开发。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Rapt Therapeutics</li>
<li>NEW LAW: Congress Approves Setup For Digital Dollar?</li>
<li>The $650 Million Bet on AI's Future</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>Trump’s AI Secret: 100X Faster Than Nvidia</li>
<li>Your Bank Account Is No Longer Safe</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Rapt Therapeutics</li>
<li>新法律：国会批准数字美元的设立？</li>
<li>对人工智能未来的 6.5 亿美元押注</li>
<li>华尔街害怕的黄金图表……</li>
<li>特朗普的人工智能秘密：比 Nvidia 快 100 倍</li>
<li>你的银行账户不再安全</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFQVA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=RAPT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rapt Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Rapt Therapeutics 吗？</h2>
</div><p>Before you consider Rapt Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rapt Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前进行购买……而 Rapt Therapeutics 并不在名单上。</p>
</div><p>While Rapt Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rapt Therapeutics 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts

Market Beat

RAPT Therapeutics

纳斯达克生物科技指数 ETF - iShares Nasdaq

生物科技 ETF - VanEck Vectors

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

RAPT Therapeutics（纳斯达克：RAPT）获得分析师一致推荐 “持有” 评级